Therapeutics Targeting TROP2 and HER3: Perspective on the Next Precision Treatment Advances Across Solid Tumors

Watch an on-demand webcast and download slides from a live symposium covering the latest on HER3- and TROP2-targeted antibody‒drug conjugates for NSCLC, breast cancer, and other solid tumors.

Share

Program Content

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.